Lactotransferrin expression is downregulated and affects the mitogen‑activated protein kinase pathway in gastric cancer Corrigendum in /10.3892/ol.2021.12504

Luo,Gengqiu; Zhou,Yanhong; Yi,Wei; Yi,Hong

doi:10.3892/ol.2015.3011

Lactotransferrin expression is downregulated and affects the mitogen‑activated protein kinase pathway in gastric cancer

Corrigendum in: /10.3892/ol.2021.12504

Authors:
- Gengqiu Luo
- Yanhong Zhou
- Wei Yi
- Hong Yi
View Affiliations

Affiliations: Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Molecular Genetics Laboratory, Cancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China, Research Center of Carcinogenesis and Targeted Therapy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: March 3, 2015 https://doi.org/10.3892/ol.2015.3011
Pages: 2409-2413

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is the second leading cause of cancer‑associated mortality worldwide. In advanced and metastatic GC, conventional chemotherapy results in limited efficacy and the average survival rate is currently approximately 10 months. Dysregulated activation of numerous genes, including zinc finger, DHHC‑type containing 14; caspase‑associated recruitment domain‑containing protein; and Ras association domain family member 10, have been implicated in GC. The tumor suppressor function of lactotransferrin (LTF) has been reported in a variety of tumors, including GC, nasopharyngeal carcinoma (NPC) and prostate cancer. However, the mechanism of the tumor suppressor function of LTF in GC remains unclear. In the present study, the expression levels of LTF in patient GC tissue samples were investigated using reverse transcription‑quantitative polymerase chain reaction, and it was demonstrated that the LTF mRNA expression level in GC tissue samples was reduced by ~20‑fold compared with the adjacent non‑cancerous tissues (t=4.56, P<0.01). A similar trend in LTF protein expression was observed by western blot analysis. Furthermore, the present study demonstrated that the mitogen‑activated protein kinase (MAPK) signaling pathway intermediates p38, c‑Jun N‑terminal kinase (JNK) and c‑Jun were highly expressed in GC tissue samples, and indicated that LTF downregulation may be associated with the dysregulation of the MAPK signaling pathway in GC tissues. In addition, the present study indicated that LTF overexpression reduced the expression of p38, JNK2 and c‑Jun in the GC cell line, SGC7901. The present study demonstrates that LTF expression is downregulated in GC tissues and that LTF may serve an important role in the dysregulation of the MAPK signaling pathway.

View Figures

View References

1	Cho JY: Molecular diagnosis for personalized target therapy in gastric cancer. J Gastric Cancer. 13:129–135. 2013. View Article : Google Scholar : PubMed/NCBI
2	Sousa JF, Ham AJ, Whitwell C, Nam KT, Lee HJ, Yang HK, et al: Proteomic profiling of paraffin-embedded samples identifies metaplasia-specific and early-stage gastric cancer biomarkers. Am J Pathol. 181:1560–1572. 2012. View Article : Google Scholar : PubMed/NCBI
3	Cui J, Xi H, Cai A, Bian S, Wei B and Chen L: Decreased expression of Sox7 correlates with the upregulation of the Wnt/β-catenin signaling pathway and the poor survival of gastric cancer patients. Int J Mol Med. 34:197–204. 2014.PubMed/NCBI
4	Oo HZ, Sentani K, Sakamoto N, Anami K, Naito Y, Uraoka N, Oshima T, Yanagihara K, Oue N and Yasui W: Overexpression of ZDHHC14 promotes migration and invasion of scirrhous type gastric cancer. Oncol Rep. 32:403–410. 2014.PubMed/NCBI
5	Lu F, Xue JX, Hu YC, Gan L, Shi Y, Yang HS and Wei YQ: CARP is a potential tumor suppressor in gastric carcinoma and a single-nucleotide polymorphism in CARP gene might increase the risk of gastric carcinoma. PLoS One. 9:e977432014. View Article : Google Scholar : PubMed/NCBI
6	Li Z, Chang X, Dai D, Deng P and Sun Q: RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer. Oncol Rep. 31:1661–1668. 2014.PubMed/NCBI
7	Legrand D: Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol. 90:252–268. 2012. View Article : Google Scholar : PubMed/NCBI
8	Legrand D, Pierce A, Elass E, Carpentier M, Mariller C and Mazurier J: Lactoferrin structure and functions. Adv Exp Med Biol. 606:163–194. 2008.PubMed/NCBI
9	Gibbons JA, Kanwar RK and Kanwar JR: Lactoferrin and cancer in different cancer models. Front Biosci (Schol Ed). 3:1080–1088. 2011. View Article : Google Scholar : PubMed/NCBI
10	Bezault J, Bhimani R, Wiprovnick J and Furmanski P: Human lactoferrin inhibits growth of solid tumors and development of experimental metastases in mice. Cancer Res. 54:2310–2312. 1994.PubMed/NCBI
11	Varadhachary A, Wolf JS, Petrak K, O'Malley BW Jr, Spadaro M, Curcio C, Forni G and Pericle F: Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy. Int J Cancer. 111:398–403. 2004. View Article : Google Scholar : PubMed/NCBI
12	Tsuda H, Sekine K, Nakamura J, Ushida Y, Kuhara T, et al: Inhibition of azoxymethane initiated colon tumor and aberrant crypt foci development by bovine lactoferrin administration in F344 rats. Adv Exp Med Biol. 443:273–284. 1998.PubMed/NCBI
13	Sekine K, Watanabe E, Nakamura J, Takasuka N, et al: Inhibition of azoxymethane-initiated colon tumor by bovine lactoferrin administration in F344 rats. Jpn J Cancer Res. 88:523–526. 1997. View Article : Google Scholar : PubMed/NCBI
14	Matsuda Y, Saoo K, Hosokawa K, Yamakawa K, Yokohira M, Zeng Y, Takeuchi H and Imaida K: Post-initiation chemopreventive effects of dietary bovine lactoferrin on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in female A/J mice. Cancer Lett. 246:41–46. 2007. View Article : Google Scholar : PubMed/NCBI
15	Li WY, Li QW, Han ZS, Jiang ZL, Yang H, Li J and Zhang XB: Growth suppression effects of recombinant adenovirus expressing human lactoferrin on cervical cancer in vitro and in vivo. Cancer Biother Radiopharm. 26:477–483. 2011. View Article : Google Scholar : PubMed/NCBI
16	Nakajima M, Shinoda I, Samejima Y, Miyauchi H, Fukuwatari Y and Hayasawa H: Lactoferrin as a suppressor of cell migration of gastrointestinal cell lines. J Cell Physiol. 170:101–105. 1997. View Article : Google Scholar : PubMed/NCBI
17	Zhou Y, Zeng Z, Zhang W, Xiong W, Wu M, Tan Y, Yi W, Xiao L, Li X, Huang C, et al: Lactotransferrin: a candidate tumor suppressor - Deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway. Int J Cancer. 123:2065–2072. 2008. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
20	Deng M, Zhang W, Tang H, Ye Q, Liao Q, Zhou Y, Wu M, Xiong W, Zheng Y, Guo X, et al: Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms. Oncogene. 32:4273–4283. 2013. View Article : Google Scholar : PubMed/NCBI
21	Ward PP, Paz E and Conneely OM: Multifunctional roles of lactoferrin: a critical overview. Cell Mol Life Sci. 62:2540–2548. 2005. View Article : Google Scholar : PubMed/NCBI
22	Rodrigues L, Teixeira J, Schmitt F, Paulsson M and Månsson HL: Lactoferrin and cancer disease prevention. Crit Rev Food Sci Nutr. 49:203–217. 2009. View Article : Google Scholar : PubMed/NCBI
23	Shaheduzzaman S, Vishwanath A, Furusato B, Cullen J, Chen Y, Bañez L, Nau M, Ravindranath L, Kim KH, Mohammed A, et al: Silencing of Lactotransferrin expression by methylation in prostate cancer progression. Cancer Biol Ther. 6:1088–1095. 2007. View Article : Google Scholar : PubMed/NCBI
24	Iijima H, Tomizawa Y, Iwasaki Y, Sato K, Sunaga N, Dobashi K, Saito R, Nakajima T, Minna JD and Mori M: Genetic and epigenetic inactivation of LTF gene at 3p21.3 in lung cancers. Int J Cancer. 118:797–801. 2006. View Article : Google Scholar : PubMed/NCBI
25	Yi HM, Li H, Peng D, Zhang HJ, Wang L, Zhao M, Yao KT and Ren CP: Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma. Oncol Res. 16:261–272. 2006.PubMed/NCBI
26	Campbell T, Skilton RA, Coombes RC, Shousha S, Graham MD and Luqmani YA: Isolation of a lactoferrin cDNA clone and its expression in human breast cancer. Br J Cancer. 65:19–26. 1992. View Article : Google Scholar : PubMed/NCBI
27	Kholodnyuk ID, Kozireva S, Kost-Alimova M, Kashuba V, Klein G and Imreh S: Down regulation of 3p genes, LTF, SLC38A3 and DRR1, upon growth of human chromosome 3-mouse fibrosarcoma hybrids in severe combined immunodeficiency mice. Int J Cancer. 119:99–107. 2006. View Article : Google Scholar : PubMed/NCBI
28	Yang Y, Li J, Szeles A, Imreh MP, Kost-Alimova M, Kiss H, Kholodnyuk I, Fedorova L, Darai E, Klein G and Imreh S: Consistent downregulation of human lactoferrin gene, in the common eliminated region 1 on 3p21.3, following tumor growth in severe combined immunodeficient (SCID) mice. Cancer Lett. 191:155–164. 2003. View Article : Google Scholar : PubMed/NCBI
29	Huang P, Han J and Hui L: MAPK signaling in inflammation-associated cancer development. Protein Cell. 1:218–226. 2010. View Article : Google Scholar : PubMed/NCBI
30	Wagner EF and Nebreda AR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 9:537–549. 2009. View Article : Google Scholar : PubMed/NCBI
31	You H, Lei P and Andreadis ST: JNK is a novel regulator of intercellular adhesion. Tissue Barriers. 1:e268452013. View Article : Google Scholar : PubMed/NCBI
32	Yuan F, Xu Z, Yang M, Wei Q, Zhang Y, Yu J, Zhi Y, Liu Y, Chen Z and Yang J: Overexpressed DNA polymerase iota regulated by JNK/c-Jun contributes to hypermutagenesis in bladder cancer. PLoS One. 8:e693172013. View Article : Google Scholar : PubMed/NCBI
33	Okada M, Shibuya K, Sato A, Seino S, Watanabe E, Suzuki S, Seino M and Kitanaka C: Specific role of JNK in the maintenance of the tumor-initiating capacity of A549 human non-small cell lung cancer cells. Oncol Rep. 30:1957–1964. 2013.PubMed/NCBI
34	Suzuki K and Matsubara H: Recent advances in p53 research and cancer treatment. J Biomed Biotechnol. 2011:9783122011. View Article : Google Scholar : PubMed/NCBI
35	Jiang L, Chang J, Zhang Q, Sun L and Qiu X: MicroRNA hsa-miR-125a-3p activates p53 and induces apoptosis in lung cancer cells. Cancer Invest. 31:538–544. 2013. View Article : Google Scholar : PubMed/NCBI
36	Marcel V, Ghayad SE, Belin S, Therizols G, Morel AP, Solano-Gonzàlez E, Vendrell JA, Hacot S, Mertani HC, Albaret MA, et al: p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. Cancer Cell. 24:318–330. 2013. View Article : Google Scholar : PubMed/NCBI
37	Wang Y, Zhang YX, Kong CZ, Zhang Z and Zhu YY: Loss of P53 facilitates invasion and metastasis of prostate cancer cells. Mol Cell Biochem. 384:121–127. 2013. View Article : Google Scholar : PubMed/NCBI